Table 1.
Characteristics of the study HCT donor/recipient pairs.
| Total (N = 18) | ||
|---|---|---|
| Recipient age at HCT (years) | ||
| Median age (IQR; years) | 59 (41–63) | |
| Female donor to male recipient | ||
| Yes | 4 (22) | |
| No | 14 (78) | |
| Primary diagnosis at HCT | ||
| Acute lymphoblastic leukemia | 1 (5.5) | |
| Acute myeloid leukemia | 11 (61) | |
| Multiple myeloma | 1 (5.5) | |
| Myelodysplastic syndrome | 2 (11) | |
| Myeloproliferative neoplasm | 3 (17) | |
| Karnofsky performance score (at conditioning for HCT) | ||
| 80 | 5 (28) | |
| 90 | 9 (50) | |
| 100 | 4 (22) | |
| Conditioning regimen | ||
| Reduced intensity | 12 (67) | |
| Myeloablative | 6 (33) | |
| Donor: COVID-19 vaccination status/COVID-19 history | ||
| Vaccinated/no COVID-19 history | 13 (72) | |
| Not vaccinated/COVID-19 history | 5 (28) | |
| Recipient: COVID-19 vaccination status COVID-19 history | ||
| Not vaccinated/no COVID-19 history | 5 (28) | |
| Not vaccinated/pre-HCT COVID-19 history | 1 (5.5) | |
| Not vaccinated/post-HCT COVID-19 history | 1 (5.5) | |
| Vaccinated pre-HCT/no COVID-19 history | 7 (39) | |
| Vaccinated pre- and post-HCT/no COVID-19 history | 1 (5.5) | |
| Vaccinated pre-HCT/post-HCT COVID-19 history | 1 (5.5) | |
| Vaccinated post-HCT/no COVID-19 history | 2 (11) | |
HCT, hematopoietic stem cell transplant; IQR, interquartile range. Values are numbers of patients (percentages) unless otherwise indicated.